Teva files NDA for ecopipam in paediatric Tourette syndrome

Teva Pharmaceutical Industries has submitted a New Drug Application to the US Food and Drug Administration for ecopipam, its investigational treatment for paediatric Tourette syndrome. If approved, ecopipam would be the first drug authorised for the condition in children in more than a decade, according to the Tel Aviv-headquartered company.

Ecopipam works by selectively blocking the dopamine D1 receptor, a mechanism distinct from the older antipsychotic agents that have historically been used off-label in Tourette syndrome and that act primarily on D2 receptors. Teva is positioning the candidate as first-in-class on the basis of that receptor selectivity, though the regulatory designation itself does not confer clinical superiority.

Phase 3 data

The NDA is supported by a randomised withdrawal study, results from which were published in JAMA Neurology ahead of the submission. The trial enrolled paediatric patients who had achieved a clinical response during an open-label run-in period, then randomised them to continue ecopipam or switch to placebo. The primary endpoint was time to relapse, measured using the Yale Global Tic Severity Scale Total Tic Score. Ecopipam showed a statistically significant advantage over placebo (p = 0.008).

The adverse event profile included somnolence in 11.1% of patients, anxiety in 9.7%, headache in 9.7%, insomnia in 8.8%, tic in 7.9%, and fatigue in 6.5%. The company described tolerability as generally acceptable, though the presence of anxiety and insomnia at those rates will likely attract scrutiny from FDA reviewers given the paediatric population. Full safety data, including longer-term follow-up, will form part of the regulatory review.

Eric Hughes, Executive Vice President for Global R&D and Chief Medical Officer at Teva, said the submission "reflects the momentum in our innovative pipeline through our recent acquisition of this important asset." Ecopipam came to Teva via a business development transaction; the company did not specify the counterparty or terms in the release.

The drug holds FDA Orphan Drug designation, reserved for conditions affecting 200,000 or fewer patients in the United States, as well as Fast Track designation, which allows for more frequent agency interactions and rolling review of completed application sections.

Market context and regulatory path

Tourette syndrome is estimated to affect roughly one percent of school-age children globally, though prevalence figures vary by diagnostic criteria. The current standard of care relies substantially on off-label use of older antipsychotics and alpha-2 agonists such as guanfacine and clonidine. No drug has received FDA approval specifically for paediatric Tourette syndrome since the early 2000s, a gap that Teva is explicitly targeting.

The D1 antagonist mechanism has been explored in other neuropsychiatric contexts over many years without yielding an approved product, which gives ecopipam a degree of scientific novelty. At the same time, the Tourette syndrome field has seen a number of late-stage programme failures in recent cycles, including several CGRP and glutamate-pathway approaches, underscoring that FDA approval is not assured even with positive Phase 3 data.

Teva's broader pipeline strategy, which the company calls its Pivot to Growth programme, is increasingly oriented toward specialist neuroscience and immunology indications where pricing power and market exclusivity are more durable than in the generics business that still accounts for the majority of its revenues. An approval in paediatric Tourette syndrome would add a rare-disease asset with Orphan Drug exclusivity, giving Teva seven years of market protection from a potential approval date. The agency's standard review clock typically runs twelve months from NDA acceptance; a PDUFA date has not yet been disclosed.